Svenska

Video Gallery

Fundamentals of the IMMray™ PanCan-d test

Clinical Diagnosis & Diagnostic Aids for Pancreatic Cancer
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021

 

Current Diagnostic Landscape for Pancreatic Cancer (PDAC)
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021

 

Laboratory Developed Tests
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021

 

Statistical Evaluation of Diagnostic Tests
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021

 

Familial/Hereditary Pancreatic Cancer Surveillance Programs: An Overview
Presented by Carrie Mansfield, MBA, Clinical Marketing Program Manager
Published February 17, 2021

 

Reimbursement in the US: An Overview
Presented by Karen Rego, MS, Sales Operations and Payer Relations Manager
Published February 17, 2021

 

Other Immunovia videos

Immunovia’s pancreatic cancer awareness campaign between August 12 to September 30, 2019 in Times Square, New York City, highlighting the importance of early detection.

 

WCVB Channel 5 News covered on the 2nd of May 2019, 5 pm EST Immunovia’s IMMray™ PanCan-d for early detection of pancreatic cancer: “Promising results reported for early detection blood test targeting pancreatic cancer”.

 


IMMray™ technology:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. Published January 2016.

 


IMMray™ technology – Short Version:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. Published November 2015.

Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports